Lorlatinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 48 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Lorlatinib is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK), and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Lorlatinib is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic kinase (ALK), and C-ros 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood-brain barrier. ALK belongs to the receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.

Lorlatinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. Lorlatinib is associated with transient elevations in serum aminotransferase levels during treatment but has not been linked to instances of clinically apparent injury that have been described with other similar kinase inhibitors.

Lorlatinib is a cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a member of pyrazoles, a member of monofluorobenzenes, an aromatic ether, a nitrile, a member of benzamides, an aza macrocycle, an aminopyridine, a cyclic ether, and an organic hetero tetracyclic compound.

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer11 which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC

Mechanism of Action

Non-small cell lung cancer (NSCLC) accounts for up to 85% of lung cancer cases worldwide and remains a particularly difficult to treat condition. The gene rearrangement of anaplastic lymphoma kinase (ALK) is a alteration that drives the development of NSCLC in a number of patients. Ordinarily, ALK is a natural endogenous tyrosine kinase receptor that plays an important role in the development of the brain and elicits activity on various specific neurons in the nervous system. Subsequnetly, lorlatinib is a kinase inhibitor with in vitro activity against ALK and number of other tyrosine kinase receptor related targets including ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of on crizotinib and other ALK inhibitors. Moreover, lorlatinib possesses the capability to cross the blood-brain barrier, allowing it to reach and treat progressive or worsening brain metastases as well. The overall antitumor activity of lorlatinib in in-vivo models appears to be dose-dependent and correlated with the inhibition of ALK phosphorylation. Although many ALK-positive metastatic NSCLC patients respond to initial tyrosine kinase therapies, such patients also often experience tumor . Various trials performed with lorlatinib, however, have demonstrated its utility to effect tumor regression in ALK-positive metastatic NSCLC patients who experience tumor progression despite current use or having already used various first and second-generation tyrosine kinase inhibitors like crizotinib, alectinib, or ceritinib.

Based on data from Study B7461001, exposure-response relationships for Grade 3 or 4 hypercholesterolemia and for any Grade 3 or 4 adverse reaction were observed at steady-state exposures achieved at the recommended , with higher probability of the occurrence of adverse reactions with increasing lorlatinib exposure. In 295 patients who received lorlatinib at the recommended dosage of 100 mg once daily and had an measurement in the same Study B7461001, the maximum mean change from for their PR interval was 16.4 ms (2-sided 90% upper confidence interval [CI] 19.4 ms). Among the 284 patients with PR interval <200 ms at baseline, 14% had PR interval prolongation ≥200 ms after starting use with lorlatinib. The prolongation of PR interval occurred in a concentration-dependent manner and atrioventricular block occurred in 1% of patients. Finally, in 275 patients who received lorlatinib at the recommended dosage in the activity-estimating portion of Study B7461001, no large mean increases from baseline in the QTcF interval (i.e., >20 ms) were detected.

Indications

  • Lorlatinib is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). In the EU, it is indicated for the treatment of adult patients with ALK-positive advanced NSCLC not previously treated with an ALK inhibitor, or whose disease has progressed after using either [alectinib] or [ceritinib], or [crizotinib] and at least one other ALK inhibitor.
  • Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
  • Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.
  • Lorlatinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer.
  • Lorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). It is the only ALK inhibitor with meaningful activity against ALK G1202R mutation in lung cancer.
  • Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer

Use in Cancer

Lorlatinib is approved to treat adults with:

  • Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body).
  • Lorlatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.

Lorlatinib is also being studied in the treatment of other types of cancer.

Contraindications

  • Lorlatinib must not be combined with strong inducers (i.e. activators) of the liver enzymes CYP3A4/5 if it can be avoided, as serious cases of liver toxicity have been observed under combination with the CYP3A4/5 inducer rifampicin
  • high
  • high amount of triglyceride in the blood
  • suicidal thoughts
  • high blood pressure
  • atrioventricular block, a type of slow heart rhythm disorder
  • a type of of the lung called interstitial pneumonitis
  • seizures
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • stage 4 ()
  • disease stage 5 (failure)

Dosage

Strengths: 25 mg; 100 mg

Non-Small Cell Lung Cancer

  • 100 mg orally once a day
  • Select patients for the treatment of metastatic non-small cell lung cancer (NSCLC) based on the presence of ALK positivity in tumor specimens.
  • Therapy should be continued until disease progresses or unacceptable toxicity.
  • For the treatment of adult patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test

Dose Adjustments

  • or renal dysfunction (CrCl 30 to 89 mL/min): No adjustment is recommended.
  • Severe renal dysfunction (CrCl 15 to less than 30 mL/min): 75 mg orally once a day

Liver Dose Adjustments

  • Mild liver dysfunction (total less than or equal to the upper limit of normal (ULN) with AST greater than ULN or total bilirubin greater than 1 to 1.5 x ULN with any AST): No adjustment recommended.
  • Moderate or severe live dysfunction: Data not available

Dose Adjustments

Dose Modifications for Adverse Reactions:

  • First dose reduction: 75 orally once a day
  • Second dose reduction: 50 mg orally once a day
  • Permanently discontinue therapy in patients who are unable to tolerate 50 mg orally once daily.

Central Nervous System Adverse Effects:

  • Grade 1: Continue at the same dose or withhold the dose until recovery to baseline; resume at the same dose or at reduced dose.
  • Grade 2 or 3: Withhold dose until recovery to Grade 0 or 1; resume at a reduced dose.
  • Grade 4: Permanently discontinue therapy.

:

Grade 4 hypercholesterolemia OR Grade 4 hypertriglyceridemia: Withhold until recovery to Grade 2 or less; resume at the same dose. If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume at a reduced dose.

Atrioventricular (AV) Block:

  • Second-degree AV block: Withhold until PR interval is less than 200 ms; resume at a reduced dose.
  • The first occurrence of complete AV block: Withhold until pacemaker placed OR PR interval is less than 200 ms; if a pacemaker is placed, resume at same dose; if no pacemaker is placed, resume at a reduced dose.
  • complete AV block: Place pacemaker or permanently discontinue this drug.

()/Pneumonitis:

  • Any Grade treatment-related ILD/pneumonitis: Permanently discontinue this drug.

:

  • Grade 3 (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg; medical intervention indicated; more than one antihypertensive drug, or more intensive therapy than previously used indicated): Withhold until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume at the same dose.
  • If Grade 3 hypertension recurs, withhold until recovery to Grade 1 or less, and resume at a reduced dose. Permanently discontinue, if adequate hypertension control cannot be achieved with optimal medical management.

Grade 4 (life-threatening consequences, urgent intervention indicated): Withhold until recovery to Grade 1 or less, and resume at a reduced dose or permanently discontinue. Permanently discontinue, if Grade 4 hypertension recurs.

Hyperglycemia:

Grade 3 (greater than 250 mg/dL) despite optimal anti-hyperglycemic therapy OR Grade 4: Withhold until hyperglycemia is adequately controlled, then resume at the next lower dosage. If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue

Other Adverse Reactions:

  • Grade 1 or 2: Continue at the same or reduced dose.
  • Grade 3 or 4: Withhold until symptoms resolve to Grade 2 or less or baseline; resume at a reduced dose.

Concomitant Use of Strong CYP450 3A Inducers:

  • This drug is contraindicated in patients taking strong CYP450 3A inducers. Discontinue strong CYP450 3A inducers for 3 plasma half-lives prior to initiating this drug.

Concomitant Use of Moderate CYP450 3A Inducers:

  • Avoid concomitant use of this drug with moderate CYP450 3A inducers.
  • If concomitant use with moderate CYP450 3A inducers is unavoidable, increase the dose of this drug to 125 mg once a day.

Dose Modification for Strong CYP450 3A Inhibitors:

  • Avoid concomitant use of this drug with strong CYP450 3A inhibitors. If concomitant use with a strong CYP450 3A inhibitor cannot be avoided, reduce the starting dose of this drug from 100 mg once a day to 75 mg orally once a day.
  • In patients who have had a reduction to 75 mg orally once a day due to adverse reactions and who initiate a strong CYP450 3A inhibitor, reduce the dose of this drug to 50 mg orally once a day.
  • If concomitant use of a strong CYP450 3A inhibitor is discontinued, increase the dose of this drug (after 3 plasma half-lives of the strong CYP450 3A inhibitor) to the dose that was used before starting the strong inhibitor.

Administration advice:

  • This drug may be taken with or without food.
  • Swallow tablets whole, do not chew, crush or split.
  • Do not ingest if tablets are broken, cracked, or otherwise not intact.
  • If a dose is missed, take the missed dose unless the next dose is due within 4 hours; do not take 2 doses at the same time to make up for a missed dose.
  • Do not take an additional dose if vomiting occurs but continue with the next scheduled dose

Monitoring:

  • Monitor blood pressure after 2 weeks and then at least monthly during treatment.
  • Monitor serum cholesterol and triglycerides before initiating treatment, after 1 and 2 months during treatment, and periodically thereafter.
  • Monitor ECG prior to initiating treatment and periodically thereafter.
  • Obtain fasting serum glucose prior to initiating treatment and monitor periodically thereafter.

Patient advice:

  • Advise the patient to read the FDA-approved patient labeling (Patient Information).
  • Inform patients of the potential risk of hepatotoxicity with the concomitant use of strong CYP450 3A inducers.
  • Advise patients to inform their healthcare providers of all medications they are taking, including prescription medicines, over-the-counter drugs, vitamins, and herbal products (e.g., St. John’s wort).
  • Advise patients to notify their healthcare provider if they experience new or worsening CNS symptoms.
  • Advise patients that initiation or an increase in the dose of lipid-lowering agents may be required, depending on measured readings.
  • Advise patients to contact their healthcare provider immediately to report new or worsening cardiac symptoms.
  • Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms.
  • Advise patients of the risks of hypertension and to promptly report signs or symptoms of hypertension to their healthcare provider and that antihypertension medications may need to be initiated or adjusted during treatment.
  • Advise patients with newly occurring hyperglycemia during treatment that antihyperglycemic medications may need to be initiated.
  • Inform patients with diabetes mellitus or glucose intolerance to monitor glucose levels periodically and that antihyperglycemic medications may need to be adjusted during treatment , depending on reading.
  • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy.
  • Advise females of reproductive potential to use effective non-hormonal contraception during treatment and for at least 6 months after the final dose.
  • Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose
  • Advise women not to breastfeed during treatment and for 7 days after the final dose.
  • Advise males of reproductive potential that this drug may transiently impair fertility.

Side Effects

The Most Common

  • weight gain
  • muscle, joint, or back pain
  • diarrhea
  • constipation
  • nausea
  • vomiting
  • tiredness
  • headache
  • vision changes
  • rash or itching
  • swelling in your arms, legs, hands and feet
  • difficulty breathing
  • shortness of breath, cough, or fever
  • numbness and tingling feeling in your joints or arms and legs
  • difficulty thinking or confusion
  • seizures
  • seeing things or hearing voices that do not exist
  • changes in mood, feeling sad or anxious
  • problems with speech
  • difficulty falling asleep or staying asleep
  • unusual dreams or nightmares
  • headache, dizziness, blurred vision, feeling faint, chest pain, or shortness of breath
  • feeling more hungry or thirsty than usual, increased urination, extreme tiredness, weakness, confusion, or breath that smells fruity

More common

  • Actions that are out of control
  • aggression
  • agitation
  • anxiety
  • black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision or other changes in vision
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, “pins and needles”, tingling, or painful sensations
  • changes in behavior
  • chills
  • cough
  • defects in intelligence, short-term memory, learning ability, and attention
  • difficult or labored breathing
  • difficulty in breathing
  • discouragement
  • dizziness
  • dry mouth
  • ear congestion
  • false or unusual sense of well-being
  • feeling sad or empty
  • fever
  • flushed, dry skin
  • fruit-like breath odor
  • headache
  • hoarseness
  • increased hunger
  • increased thirst
  • increased urination
  • irritability
  • lack of appetite
  • loss of interest or pleasure
  • loss of voice
  • lower back or side pain
  • nausea
  • nervousness
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • runny or stuffy nose
  • seeing, hearing, or feeling things that are not there
  • skin rash
  • slow or fast heartbeat
  • sneezing
  • sore throat
  • stomach pain
  • sweating
  • swelling
  • talking, feeling, and acting with excitement
  • thoughts of killing oneself
  • tightness in the chest
  • trouble concentrating
  • trouble sleeping
  • trouble breathing
  • unexplained weight loss
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
  • weakness in the arms, hands, legs, or feet

Rare

  • Abnormal dreams
  • back pain
  • constipation
  • difficulty in moving
  • difficulty in speaking
  • drowsiness
  • joint pain
  • muscle aches, cramps, pains, or stiffness
  • pain in the arms or legs
  • sleep talking
  • swollen joints

Drug Interaction

Pregnancy and Lactation

Pregnancy

Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], LORBRENA can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on LORBRENA use in pregnant women. Administration of lorlatinib to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in malformations, increased post-implantation loss, and abortion at maternal exposures that were equal to or less than the human exposure at the recommended dose of
100 mg once daily based on AUC (see Data). Advise a pregnant woman of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Lactation

There are no data on the presence of lorlatinib or its metabolites in either human or animal milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment with LORBRENA and for 7 days after the final dose.

Why is this medication prescribed?

Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

How should this medicine be used?

Lorlatinib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Take lorlatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lorlatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.

Swallow the tablets whole; do not split, chew, or crush them. Do not take tablets that are already broken or cracked.

Your doctor may decrease your dose or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with lorlatinib. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking lorlatinib,

  • tell your doctor and pharmacist if you are allergic to lorlatinib, any other medications, or any of the ingredients in lorlatinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor if you are taking carbamazepine (Epitol, Equetro, Carbatrol, Tegretol, Teril), efavirenz (Sustiva, in Atripla), nevirapine (Viramune), phenobarbital, phenytoin (Dilantin, Phenytek), pioglitazone (Actos, in Actoplus, Duetact), rifabutin (Mycobutin), rifampin (Rifadin, Rimactane, in Rifamate, Rifater), or St. John’s wort. Your doctor will probably tell you not to take lorlatinib if you are taking one or more of these medications.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); calcium channel blockers such as amlodipine (Norvasc), diltiazem (Cardizem, Dilacor, Tiazac), felodipine (Plendil), nifedipine (Adalat, Procardia), nisoldipine (Sular), and verapamil (Calan, Covera); certain medications to treat high cholesterol such as atorvastatin (Lipitor) and lovastatin (Mevacor); clarithromycin (Biaxin, in Prevpac); cyclosporine (Gengraf, Neoral, Sandimmune); diazepam (Valium); erythromycin (E.E.S, Erytab, Eryped); certain medications to treat HIV including atazanavir (Reyataz, in Evotaz), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, in Technivie), or saquinavir (Invirase); fluconazole; itraconazole (Onmel, Sporanox); ketoconazole; midazolam; nefazodone; oral contraceptives (birth control pills); quinidine (in Nuedexta); sildenafil (Revatio, Viagra); sirolimus (Rapamune); tacrolimus (Prograf); tadalafil (Adcirca, Cialis); trazodone; triazolam (Halcion); or vardenafil (Levitra, Staxyn). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with lorlatinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had high blood pressure, an irregular heartbeat, diabetes or high blood sugar levels, depression, seizures, high levels of cholesterol and other fatty substances in the blood, or kidney or lung disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. Lorlatinib may interfere with the action of hormonal contraceptives (birth control pills, patches, rings, implants, or injections), so you should not use these as your only method of birth control during your treatment. You must use a non-hormonal birth control such as a barrier method (device that blocks sperm from entering the uterus such as a condom or a diaphragm). Ask your doctor to help you choose a method of birth control that will work for you. If you are female, you will need to take a pregnancy test before you start treatment and should use non-hormonal birth control to prevent pregnancy during your treatment and for 6 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking lorlatinib, call your doctor immediately. Lorlatinib may harm the fetus.
  • tell your doctor if you are breast-feeding. You should not breast-feed while you are taking lorlatinib and for 7 days after your final dose.
  • you should know that this medication may temporarily decrease fertility in men. Talk to your doctor about the risks of taking lorlatinib.

What special dietary instructions should I follow?

Talk to your doctor about eating grapefruit and drinking grapefruit juice while taking this medication.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is within 4 hours of the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/210868Orig1s004ltr.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210868.pdf
  5. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/210868Orig1s002ltr.pdf
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Lorlatinib
  7. https://pubchem.ncbi.nlm.nih.gov/compound/78162481
  8. https://go.drugbank.com/drugs/DB12130
  9. https://www.cancer.gov/about-cancer/treatment/drugs/lorlatinib
  10. https://www.drugs.com/lorlatinib.html
  11. https://medlineplus.gov/druginfo/meds/a619005.html
  12. https://www.mayoclinic.org/drugs-supplements/lorlatinib-oral-route/side-effects/drg-20452266?p=1
  13. https://en.wikipedia.org/wiki/Lorlatinib
  14. https://www.webmd.com/drugs/2/drug-176414/lorlatinib-oral/details/list-contraindications
  15. CAS Common Chemistry
    https://creativecommons.org/licenses/by-nc/4.0/
    https://commonchemistry.cas.org/detail?cas_rn=1454846-35-5
  16. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=1454846355
    https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
  17. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    https://www.drugbank.ca/drugs/DB12130
  18. EPA DSSTox
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/DTXSID201027944
    https://comptox.epa.gov/dashboard/chemical-lists/
  19. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/253391
  20. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/OSP71S83EU
  21. ChEBI
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:143117
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  22. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
  23. LiverTox
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Lorlatinib/
  24. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C113655
    https://ncit.nci.nih.gov
  25. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3286830/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  26. Comparative Toxicogenomics Database (CTD)
    http://ctdbase.org/about/legal.jsp
    https://ctdbase.org/detail.go?type=chem&acc=C000590786
  27. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/LORLATINIB
  28. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476
    https://www.guidetopharmacology.org/targets.jsp
  29. Therapeutic Target Database (TTD)
    https://idrblab.net/ttd/data/drug/details/D04DYC
    https://idrblab.net/ttd/data/drug/details/D0AF6O
    https://idrblab.net/ttd/data/drug/details/D0N8YJ
  30. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  31. DailyMed
    https://www.nlm.nih.gov/copyright.html
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=LORLATINIB
  32. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua
  33. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  34. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  35. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    https://www.whocc.no/atc_ddd_index/
  36. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  37. Metabolomics Workbench
    https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=153176
  38. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/lorlatinib
  39. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  40. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/2103164
  41. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5P8
  42. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  43. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  44. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=30052128-904871204
  45. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=30052128-904867875
  46. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q27285820
  47. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/mesh/2001857
    http://www.nlm.nih.gov/mesh/meshhome.html
  48. KEGG
    https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08301.keg
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
    http://www.genome.jp/kegg-bin/get_htext?br08332.keg
  49. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  50. NORMAN Suspect List Exchange
    https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  51. PATENTSCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/393507331

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Medicines to learn about

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Lorlatinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.